A Study of Two Different Formulations of LY3209590 in Healthy Participants

• Status: Completed
• Trial end date: 2021-09-03
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to look at the amount of the study drug, LY3209590, that gets into the blood stream and how long it takes the body to get rid of LY3209590 when given as different formulations. The tolerability of LY3209590 will also be evaluated and information about any side effects experienced will be collected. The study will last up to 142 days.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Are overtly healthy males or non-pregnant females. Additionally, women of childbearing potential must test negative for pregnancy

• Have a body mass index (BMI) of 18 to 35 kilograms per square meter (kg/m²), inclusive at screening

• Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study

• Have veins suitable for blood sampling

• Have given written informed consent approved by Lilly and the ethical review board governing the site

Exclusion Criteria:

• Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study

• Are women who are pregnant or lactating

• Have a history of multiple and/or severe allergic reactions

• Show clinical evidence of HIV, hepatitis C, or hepatitis B, and/or test positive

• Regularly use known drugs of abuse or with positive drug results